CD274 and head and neck squamous cell carcinoma: For example, in the CheckMate 141 study of nivolumab in platinum-refractory R/M HNSCC, PD-L1 was assessed at expression levels of ≥1%, ≥5%, and ≥10% in a minimum of 100 tumor cells (TC) that could be evaluated (10).